Navigation Links
MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE,Molecule

- New Compound Targeting Receptor Tyrosine Kinase EphA2 Shows Tumor Destruction at Low Dose Levels in Preclinical Models -

GAITHERSBURG, Md. and CARLSBAD, Calif., April 19, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc. and Micromet, Inc. today announced that published proof-of-concept data with a new BiTE(R) molecule (bscEphA2xCD3) show that the compound killed tumor cells at dose levels considerably below those required by classical monoclonal antibody-based therapies. The in vitro and in vivo data, collected from cell culture experiments conducted under the companies' BiTE(R) technology research collaboration, were published in the April 15, 2007 issue of Cancer Research.

BiTE molecules represent a novel class of drugs that function as bi- specific T-cell engagers. They are unique in their ability to enable the body's killer T cells to recognize and attack tumor and target cells, leaving normal cells unharmed. bscEphA2xCD3 is a BiTE molecule targeting the tyrosine kinase receptor EphA2, which is frequently overexpressed on a wide variety of solid tumors.

"The results of this study show that a receptor tyrosine kinase may be an appropriate target for a BiTE molecule," said Patrick Baeuerle, Ph.D., Micromet's Chief Scientific Officer. "This highlights the breadth of the BiTE technology for creating molecules that target different kinds of antigens. Recognition of selected sites on a target antigen may provide a means to widen the therapeutic window for this highly potent therapeutic approach."

In the preclinical study, tumor cell destruction approached 100 percent even at low ratios of effector T cells to target cells. In animal models, the BiTE compound redirected unstimulated human T cells to inhibit outgrowth of transplanted human tumor cells. Time-lapsed videomicroscopy showed that bscEphA2xCD3 triggered T cells to destruct tumor cells overexpressing EphA2, but spared normal cells wher
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
11. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: MedImmune and Micromet Publish Data Novel Anti Cancer BiTE Molecule
(Date:5/22/2013)...  Flagship Ventures, a leading venture capital and ... today announced the appointment of Stephane ... this role, Mr. Bancel will provide strategic counsel ... addition to working closely with companies in the ... and Chief Executive Officer of Moderna Therapeutics, a ...
(Date:5/22/2013)...  Grifols, a global healthcare company based in ... study demonstrating that a higher dose of PROLASTIN © ... the alpha 1 protein in patients with alpha ... within the normal range for healthy individuals. AAT deficiency ... of the alpha 1 proteinase inhibitor (A1PI) protein ...
(Date:5/22/2013)... 2013  Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical ... unmet medical needs, today announced the appointment of ... its Board of Directors. Dr. Almenoff has extensive experience ... stage drug development. "We are delighted ... Irach Taraporewala, CEO of Ohr Pharmaceutical. "She offers tremendous ...
Breaking Medicine Technology:Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors 2Ohr Pharmaceutical Appoints June S. Almenoff to Board of Directors 3
... N.Y., Sept. 15 Sono-Tek Corporation (OTC Bulletin Board: ... at the symposium of advanced coating technologies, whose aim ... on coating science and technology.  The symposium was attended ... medical and energy projects and by academia from around ...
... U.S. Food and Drug Administration is notifying health care ... tablets and solution used by children and adolescents receiving ... to prevent drug overdosing of children with low body ... creatinine. The revised dosing instructions now appear in the ...
Cached Medicine Technology:Sono-Tek Presents at the 15th International Coating Science and Technology Symposium (ISCST, St. Paul, MN) 2FDA Issues New Dosing Guide for Children Using Valcyte 2
(Date:5/22/2013)... Texas (PRWEB) May 22, 2013 Beginning ... On” in the Conrad Foundation’s Spirit of Innovation ... and technical plan competition, free and open to students ... , The Spirit of Innovation Challenge celebrates the life ... to walk on the Moon. The program challenges teens ...
(Date:5/22/2013)... Rye Brook, New York (PRWEB) May 22, 2013 ... clinic that specializes in combining treatments for optimal results, ... thicken thin skin on the neck. The practice ... and seen dramatic results. , “Basically, this approach is ... neck lift,” says Westchester dermatologist Dr. Michelle ...
(Date:5/22/2013)... JoVE will publish details of a ... relation to a patients age. The method is demonstrated by ... Einstein College of Medicine. Dr. Atzmon hopes that the dissemination ... genetic thermometer to assess a patients health in relation to ... publication will feature a technique that measures telomere length. ...
(Date:5/22/2013)... GA (PRWEB) May 22, 2013 ... agency, JD Media Surge, LLC, E-Dentists.com has launched ... The blog will feature numerous topics of interest ... treatment options and dental health. , http://www.E-Dentists.com/Blog/ ... of dental Internet marketing. In addition to addressing ...
(Date:5/22/2013)... May 2013, Paris, France: Results from a ... today question whether bivalirudin is superior to ... showing similar 30-day mortality in patients with ... undergoing percutaneous coronary intervention (PCI)., European and ... as an alternative to unfractionated heparin plus ...
Breaking Medicine News(10 mins):Health News:Conrad Foundation Announces 2013-2014 Spirit of Innovation Challenge Launch Date 2Health News:Westchester Dermatologist Abadir Associates Offers New Neck Lift Surgery Alternative 2Health News:How healthy are you for your age? 2Health News:Dental SEO Blog Launched by E-Dentists.com in Partnership with JD Media Surge, LLC 2Health News:Registry questions superiority of bivalirudin over heparin 2
... the perfect night,s sleepDALLAS, April 7 ... a free-standing, patent pending kiosk that contains all of the ... product breaks the mold for the industry standards of soft, ... an individual,s sleep preference of side, back or stomach sleeper. ...
... strategic analysis of technologies. , ... Atlanta, GA ... global leader in legal consulting, technology and outsourcing, today announced it ... vendor of software tools that enable rapid comprehension and decision making ...
... of anti-aging injections continue, as do false claims and risk ... ... Physicians Coalition for Injectable Safety , There is no debating ... themselves, particularly in appearance enhancing treatments that restore youth and erase ...
... traits of wisdom appear to follow a universal path ... -- Wisdom appears to be more than a subjective ... circuits and pathways, suggest U.S. researchers who compiled the ... this type of research could potentially lead to interventions ...
... therapy, household changes added 3.5 years on average, study ... home-based program for seniors that includes occupational and physical ... help people live longer, new research found. , In ... 3.5 years of lifespan compared to those who didn,t, ...
... Community Hospice of Northeast Florida , in collaboration ... across the country to complete their advance healthcare directives ... designation of April 16, 2009 ... recent gains in public awareness of the need for ...
Cached Medicine News:Health News:Now Available Online, The Pillow Bar is the Right Mix of Luxury and Necessity 2Health News:UnitedLex Announces Strategic Alliance with Oval Ideas to Enable Superior Patent Analytics 2Health News:Physicians Coalition for Injectable Safety Says There are No Substitutes for Cosmetic Injections, Offers Solutions 2Health News:Physicians Coalition for Injectable Safety Says There are No Substitutes for Cosmetic Injections, Offers Solutions 3Health News:Physicians Coalition for Injectable Safety Says There are No Substitutes for Cosmetic Injections, Offers Solutions 4Health News:Pathway to Wisdom May Be Found in Brain Circuitry 2Health News:Home-Based Program Extends Seniors' Lives 2Health News:Home-Based Program Extends Seniors' Lives 3Health News:Community Hospice Supports National Healthcare Decisions Day 2Health News:Community Hospice Supports National Healthcare Decisions Day 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: